17β-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: A prognostic factor via potential regulation of fatty acid synthesis

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1392-1399

  Nagasaki, Shuji ^a,c   Suzuki, Takashi ^a   Miki, Yasuhiro ^a   Akahira, Jun Ichi ^a   Kitada, Kunio ^e   Ishida, Takanori ^b   Handa, Hiroshi ^d   Ohuchi, Noriaki ^b   Sasano, Hironobu ^a,b  

^a Department of Pathology ^*  (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Grelan Pharmaceutical Co Ltd   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^e CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; ESTRADIOL; MESSENGER RNA; PROSTAGLANDIN; SMALL INTERFERING RNA; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 12; UNCLASSIFIED DRUG; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3; 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3; FATTY ACID; HYDROXYSTEROID DEHYDROGENASE; RNA;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FATTY ACID SYNTHESIS; FEMALE; GAS CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CELL DIVISION; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; RNA INTERFERENCE;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL DIVISION; ESTRADIOL; FATTY ACIDS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 60549099416     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0821     Document Type: Article

References (40)

1. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17 β-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000; 25:1-16.
2. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005;12:701-20.
3. Nakamura Y, Suzuki T, Nakabayashi M, et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005;12:101-7.
4. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 2000;82: 518-23.
5. Moeller G, Adamski J. Multifunctionality of human 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:47-55.
6. Luu-The V, Tremblay P, Labrie F. Characterization of type 12 17β-hydroxysteroid dehydrogenase, an isoform of type 3 17β- hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20:437-43.
7. Moon YA, Horton JD. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem 2003;278:7335-43.
8. Sakurai N, Miki Y, Suzuki T, et al. Systemic distribution and tissue localizations of human 17β-hydroxysteroid dehydrogenase type 12. J Steroid Biochem MolBiol2006; 99:174-81.
9. Song D, Liu G, Luu-The V, et al. Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 2006;101:136-44.
10. Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stal O. 17β- Hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res 2006;66:11471-7.
11. Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 2006;66:535-42.
12. Niino YS, Irie T, Takaishi M, et al. PKCθ II, a new isoform of protein kinase C specifically expressed in the seminiferous tubules of mouse testis. J Biol Chem 2001;276:36711-7.
13. Suzuki T, Hayashi S, Miki Y, et al. Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 2006;13:233-50.
14. Day JM, Foster PA, Tutill HJ et al. 17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 2008;122:1931-40.
15. Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor β isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 2002;71:249-55.
16. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 1997;66:1513-22S.
17. Reyes N, Reyes I, Tiwari R, Geliebter J. Effect of linoleic acid on proliferation and gene expression in the breast cancer cell line T47D. Cancer Lett 2004;209:25-35.
18. Razanamahefa L, Prouff S, Bardon S. Stimulatory effect of arachidonic acid on T-47D human breast cancer cell growth is associated with enhancement of cyclin D1 mRNA expression. Nutr Cancer 2000;38:274-80.
19. Schneiter R, Hitomi M, Ivessa AS, Fasch EV, Kohlwein SD, Tartakoff AM. A yeast acetyl coenzyme A carboxylase mutant links very-long-chain fatty acid synthesis to the structure and function of the nuclear membrane-pore complex. Mol Cell Biol 1996;16:7161-72.
20. Schneiter R, Brugger B, Amann CM, et al. Identification and biophysical characterization of a very-long-chain-fatty-acid-substituted phosphatidylino-sitol in yeast subcellular membranes. Biochem J 2004;381:941-9.
21. McMahon A, Butovich IA, Mata NL, et al. Retinal pathology and skin barrier defect in mice carrying a Stargardt disease-3 mutation in elongase of very long chain fatty acids-4. Mol Vis 2007;13:258-72.
22. Vasireddy V, Uchida Y, Salem N, Jr., et al. Loss of functional ELOVL4 depletes very long-chain fatty acids (> or = C28) and the unique ω-O-acylceramides in skin leading to neonatal death. Hum Mol Genet 2007;16:471-82.
23. Leonard AE, Kelder B, Bobik EG, et al. Identification and expression of mammalian long-chain PUFA elongation enzymes. Lipids 2002;37:733-40.
24. Poulos A, Beckman K, Johnson DW, et al. Very long-chain fatty acids in peroxisomal disease. AdvExp Med Biol 1992;318:331-40.
25. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog Lipid Res 2006;45:237-49.
26. Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J 1994;8:1248-59.
27. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004;101:415-6.
28. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclo-oxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
29. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
30. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclo-oxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004;45:47-54.
31. Alo' PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996;77:474-82.
32. Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma ofthe prostate. Urology1995;45: 81-6.
33. Gansler TS, Hardman W III, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-92.
34. Innocenzi D, Alo PL, Balzani A, et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003;30:23-8.
35. Krontiras H, Roye GD, Beenken SE, et al. Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue. Head Neck 1999;21:325-9.
36. Kusakabe T, Nashimoto A, Honma K, Suzuki T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 2002;40:71-9.
37. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000;31:1068-73.
38. Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997;150:201-8.
39. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immu-nohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 1996;27:917-21.
40. Camassei FD, Jenkner A, Rava L, et al. Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: an interinstitutional study. Med Pediatr Oncol 2003;40:302-8.